Why Is Arbutus Biopharma Stock Gaining Friday?
Arbutus Biopharma (ABUS) stock rises after announcing a $230M stock buyback via a modified Dutch auction. Get the offer details.
Read original at benzingaStocks · News reference
Roivant's Priovant Says FDA Approved LISRAYA For Dermatomyositis In Adults, First Targeted Therapy For The Disease; Available In U.S. Immediately
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 27, 2026, 7:29 PM
- Checked
- Aug 27, 2026, 7:29 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Citigroup Maintains Buy on Roivant Sciences, Raises Price Target to $46
Citigroup analyst Samantha Semenkow maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $42 to $46.
Read original at benzingaGuggenheim Maintains Buy on Roivant Sciences, Raises Price Target to $42
Guggenheim analyst Yatin Suneja maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $36 to $42.
Read original at benzinga